drugset
drugset / Trial / NCT00518284

Prevention of Restenosis Following Revascularization

NCT00518284 ↗

Phase 2 Terminated 6 enrolled Celgene Corporation
RandomizedParallel-groupOpen-labelPrevention

Summary

The purpose of this study is to investigate the prevention of Restenosis following Revascularization of the superficial Femoral Artery (SFA)

Timeline

Start
2008-01
Primary completion
2009-08
Completion
2009-09

Outcome

Outcome not reported

Stopped: “Study was terminated due to changing sponsor priorities, and was not based on safety or outcomes data.”

Drugs

EvaluationDrugModalityDoseRoute
Subject Paclitaxel Small molecule 45 mg/m2 Other

Indications

peripheral vascular disease